Labcorp's Q2 2026 results were strong with revenue and EPS beating expectations, leading to a revised, higher full-year 2026 guidance. Both Diagnostics and Biopharma segments showed robust growth, with significant margin expansion driven by organic growth and strategic initiatives. Q2 revenue of $3.7B, up 5.8% YoY; adjusted EPS of $4.99, up 14.9% YoY.
Buzzberg readRaised full-year revenue and EPS guidanceLabcorp's Q2 2026 results were strong with revenue and EPS beating expectations, leading to a revised, higher full-year 2026 guidance. Both Diagnostics and Biopharma segments showed robust growth, with significant margin expansion driven by organic growth and strategic initiatives. Q2 revenue of $3.7B, up 5.8% YoY; adjusted EPS of $4.99, up 14.9% YoY.Read full analysisCollapse analysis
Labcorp's Q2 2026 results were strong with revenue and EPS beating expectations, leading to a revised, higher full-year 2026 guidance. Both Diagnostics and Biopharma segments showed robust growth, with significant margin expansion driven by organic growth and strategic initiatives. Q2 revenue of $3.7B, up 5.8% YoY; adjusted EPS of $4.99, up 14.9% YoY.
Raised FY26 revenue growth midpoint to 5.85% (from 5.55%) and EPS midpoint to $18.325 (from $18.025).
Diagnostics organic revenue growth 3.6%, driven by volume and price mix; BLS organic constant currency growth 6.2%.
Both operating segments expanded margins: Diagnostics +50bps, BLS +130bps in Q2.
Revenue$3.7311B
+5% QoQ
EPS$4.99
+17% QoQ
Gross margin29.8%
reported
Op margin12.1%
reported
What changed this quarter
01
Guidance
Raised full-year revenue and EPS guidance
Guidance · revenue to 5.85%
02
Demand
BLS book-to-bill strong at 1.14
Management repeatedly emphasized strong quarterly performance, raised full-year guidance, and expressed optimism about pipeline and growth opportunities, underpinning a confident tone.
03
Demand
Specialty testing grows double-digits in first half
BLS book-to-bill strong at 1.14. Management repeatedly emphasized strong quarterly performance, raised full-year guidance, and expressed optimism about pipeline and growth opportunities, underpinning a confident tone.
04
Guidance
ACA impact estimate unchanged at 30 basis points
Guidance · revenue to 5.85%
AI, capex & demand read
AI
Platform & monetization
Management discussed leveraging AI to create differentiated customer experiences, enhance productivity, and transform the business, including launching the AI-powered MyLabCorp app and broadening collaboration with Epic to make tests available on its Aura platform. AI is seen as a driver of innovation and efficiency, but no specific financial metrics were provided.
Demand
Bookings & conversion
BLS book-to-bill strong at 1.14. Management repeatedly emphasized strong quarterly performance, raised full-year guidance, and expressed optimism about pipeline and growth opportunities, underpinning a confident tone.
Capex
Investment and capacity
Capital expenditures are planned at approximately 4% of revenue, with no change to the full-year free cash flow guidance of $1.24 billion to $1.36 billion. The quarter saw planned increases in capital expenditures, consistent with ongoing investments in technology and innovation.
Tone · Confident
Management repeatedly emphasized strong quarterly performance, raised full-year guidance, and expressed optimism about pipeline and growth opportunities, underpinning a confident tone.
Supply-chain alpha
A1
LabCorp is seeing a shift to more tests per access, indicating higher complexity and per-patient value, driven by specialties like oncology.
“we continue to see consistent and slight growth in test per session quarter in and quarter out.”
… ColoSense nationwide, the first FDA-approved RNA-based colorectal cancer screening test with an at-home collection. With Medicare and expanding commercial payer coverage, this test increases patient access to screening and enables earlier detection. And we entered into a clinical trial collaboration with Bob Chase Cancer Center to evaluate LabCorp's Plasma Detect Genome MRD and patients at risk of early-stage non-small-cell lung cancer reoccurrence. We expanded nationwide access to Roche's FDA-approved companion diagnostic for people living with prostate cancer who may now be eligible for combination treatment with AstraZeneca's targeted therapy. And we added an advanced DPYD genotyping test to our portfolio that helps identify patients at risk for severe treatment-related toxicity from certain chemotherapies. Beyond our priority specialty areas, we continue to advance testing solutions across a broad range of important health conditions. We signed an agreement to broaden nationwide access to myolaris KPDX, a first-of-its-kind non-invasive test that supports surveillance of graft injury, including rejection, following a kidney transplant. For patients at risk of liver disease, …
… collection. With Medicare and expanding commercial payer coverage, this test increases patient access to screening and enables earlier detection. And we entered into a clinical trial collaboration with Bob Chase Cancer Center to evaluate LabCorp's Plasma Detect Genome MRD and patients at risk of early-stage non-small-cell lung cancer reoccurrence. We expanded nationwide access to Roche's FDA-approved companion diagnostic for people living with prostate cancer who may now be eligible for combination treatment with AstraZeneca's targeted therapy. And we added an advanced DPYD genotyping test to our portfolio that helps identify patients at risk for severe treatment-related toxicity from certain chemotherapies. Beyond our priority specialty areas, we continue to advance testing solutions across a broad range of important health conditions. We signed an agreement to broaden nationwide access to myolaris KPDX, a first-of-its-kind non-invasive test that supports surveillance of graft injury, including rejection, following a kidney transplant. For patients at risk of liver disease, LabCorp's blood-based test, MASH-Next, secured Medicare coverage beginning in mid-August, expanding …
🍪 Cookies
We use cookies to operate this site and for analytics. Declining won't affect your access to content.